Predictors of slow progression to diabetes in children with multiple islet autoantibodies

Journal of Autoimmunity

Volumn 72, Issue , 2016, Pages 113-117

  Steck, Andrea K ^a   Dong, Fran ^a   Waugh, Kathleen ^a   Frohnert, Brigitte I ^a   Yu, Liping ^a   Norris, Jill M ^b   Rewers, Marian J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Food Science and Human Nutrition   (United States)

Author keywords

Islet autoimmunity; Multiple islet autoantibodies; Predictors for diabetes; Rate of progression to diabetes; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; GLUTAMATE DECARBOXYLASE ANTIBODY; HLA ANTIGEN; IA 2 ANTIBODY; INSULIN ANTIBODY; UNCLASSIFIED DRUG; ZNT8 ANTIBODY; GLUTAMATE DECARBOXYLASE; HLA DR ANTIGEN;

AGE; ARTICLE; AUTOIMMUNITY; CHILD; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; GENETICS; GENOTYPE; IMMUNOLOGY; INFANT; MULTIVARIATE ANALYSIS; PANCREAS ISLET; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS;

AUTOANTIBODIES; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; GENOTYPE; GLUTAMATE DECARBOXYLASE; HLA-DR ANTIGENS; HUMANS; INFANT; INSULIN ANTIBODIES; ISLETS OF LANGERHANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS;

EID: 84975263470     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.05.010     Document Type: Article

References (29)

1. [1] Orban, T., Sosenko, J.M., Cuthbertson, D., Krischer, J.P., Skyler, J.S., Jackson, R., et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diab. Care 32:12 (2009 Dec), 2269–2274.
2. [2] Siljander, H.T., Simell, S., Hekkala, A., Lahde, J., Simell, T., Vahasalo, P., et al. Predictive characteristics of diabetes-associated autoantibodies among children with HLA-conferred disease susceptibility in the general population. Diabetes 58:12 (2009 Dec), 2835–2842.
3. [3] Bingley, P.J., Gale, E.A., Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetology 49:5 (2006 May), 881–890.
4. [4] Yu, L., Cuthbertson, D.D., Maclaren, N., Jackson, R., Palmer, J.P., Orban, T., et al. Expression of GAD65 and islet cell antibody (ICA512) autoantibodies among cytoplasmic ICA+ relatives is associated with eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 50:8 (2001 Aug), 1735–1740.
5. [5] Greenbaum, C., Palmer, J.P., Kuglin, B., Kolb, H., Laboratories, Participating, Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J. Clin. Endocrinol. Metab. 74:5 (1992), 1040–1044.
6. [6] Baekkeskov, S., Aanstoot, H.-J., Christgau, S., Reetz, A., Solimena, M., Cascalho, M., et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase [published erratum appears in Nature 1990 Oct 25;347(6295):782]. Nature 347:6289 (1990), 151–156.
7. [7] Gianani, R., Rabin, D.U., Verge, C.F., Yu, L., Babu, S.R., Pietropaolo, M., et al. ICA512 autoantibody radioassay. diab 44 (1995), 1340–1344.
8. [8] Wenzlau, J.M., Moua, O., Sarkar, S.A., Yu, L., Rewers, M., Eisenbarth, G.S., et al. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann. N. Y. Acad. Sci. 1150 (2008 Dec), 256–259.
9. [9] Ziegler, A.G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:23 (2013 Jun 19), 2473–2479.
10. [10] Vardi, P., Ziegler, A.G., Matthews, J.H., Dib, S., Keller, R.J., Ricker, A.T., et al. Concentration of insulin autoantibodies at onset of type I diabetes. Inverse log-linear correlation with age. Diab. Care 11:9 (1988), 736–739.
11. [11] Steck, A.K., Johnson, K., Barriga, K.J., Miao, D., Yu, L., Hutton, J.C., et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diab. Care 34:6 (2011 Jun), 1397–1399.
12. [12] Achenbach, P., Hummel, M., Thumer, L., Boerschmann, H., Hofelmann, D., Ziegler, A.G., Characteristics of rapid vs slow progression to type 1 diabetes in multiple islet autoantibody-positive children. Diabetology 56:7 (2013 Jul), 1615–1622.
13. [13] Rewers, M., Bugawan, T.L., Norris, J.M., Blair, A., Beaty, B., Hoffman, M., et al. Newborn screening for HLA markers associated with iddm: diabetes autoimmunity study in the young (DAISY). Diabetology 39 (1996), 807–812.
14. [14] Yu, L., Rewers, M., Gianani, R., Kawasaki, E., Zhang, Y., Verge, C.F., et al. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J. Clin. Endocrinol. Metab. 81 (1996), 4264–4267.
15. [15] Steck, A.K., Vehik, K., Bonifacio, E., Lernmark, A., Ziegler, A.G., Hagopian, W.A., et al. Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the environmental Determinants of diabetes in the young (TEDDY). Diab. Care 38:5 (2015 May), 808–813.
16. [16] Yu, L., Simone, E., Modification to Combined GAD65/ICA512 Radioassay for general population screening. Diabets(Suppl. 1), 1996, 45.
17. [17] Yu, L., Miao, D., Scrimgeour, L., Johnson, K., Rewers, M., Eisenbarth, G.S., Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 61:1 (2012 Jan), 179–186.
18. [18] Miao, D., Guyer, K.M., Dong, F., Jiang, L., Steck, A.K., Rewers, M., et al. GAD65 autoantibodies detected by electrochemiluminescence (ECL) assay identify high risk for type 1 diabetes. Diabetes 62:12 (2013 Dec), 4174–4178.
19. [19] Mirel, D.B., Valdes, A.M., Lazzeroni, L.C., Reynolds, R.L., Erlich, H.A., Noble, J.A., Association of IL4R haplotypes with type 1 diabetes. Diabetes 51:11 (2002 Nov), 3336–3341.
20. [20] Steck, A.K., Dong, F., Wong, R., Fouts, A., Liu, E., Romanos, J., et al. Improving prediction of type 1 diabetes by testing non-HLA genetic variants in addition to HLA markers. Pediatr. Diab. 15:5 (2014 Aug), 355–362.
21. [21] Hummel, M., Bonifacio, E., Schmid, S., Walter, M., Knopff, A., Ziegler, A.G., Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann. Intern. Med. 140:11 (2004 Jun 1), 882–886.
22. [22] Achenbach, P., Warncke, K., Reiter, J., Naserke, H.E., Williams, A.J., Bingley, P.J., et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 53:2 (2004 Feb), 384–392.
23. [23] Decochez, K., De Leeuw, I.H., Keymeulen, B., Mathieu, C., Rottiers, R., Weets, I., et al. IA-2 autoantibodies predict impending type I diabetes in siblings of patients. Diabetology 45:12 (2002 Dec), 1658–1666.
24. [24] Yu, L., Boulware, D.C., Beam, C.A., Hutton, J.C., Wenzlau, J.M., Greenbaum, C.J., et al. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diab. Care 35:6 (2012 Jun), 1213–1218.
25. [25] Sosenko, J.M., Skyler, J.S., Palmer, J.P., Krischer, J.P., Yu, L., Mahon, J., et al. The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients. Diab. Care 36:9 (2013 Sep), 2615–2620.
26. [26] Nakayama, M., Abiru, N., Moriyama, H., Babaya, N., Liu, E., Miao, D., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435:7039 (2005 May 12), 220–223.
27. [27] Sosenko, J.M., Krischer, J.P., Palmer, J.P., Mahon, J., Cowie, C., Greenbaum, C.J., et al. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diab. Care 31:3 (2008 Mar), 528–533.
28. [28] Sosenko, J.M., Skyler, J.S., Mahon, J., Krischer, J.P., Beam, C.A., Boulware, D.C., et al. The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes. Diab. Care 35:7 (2012 Jul), 1552–1555.
29. [29] Yu, L., Dong, F., Miao, D., Fouts, A.R., Wenzlau, J.M., Steck, A.K., Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diab. Care 36:8 (2013 Aug), 2266–2270.